Here are five takeaways:
1. As part of the partnership, Takeda has the option to acquire Altos beginning on the agreement date and lasting until the completion of Altos’ proprietary compound’s Phase 1 clinical trials.
2. Altos is developing the proprietary compound to treat nausea and vomiting symptoms related to gastroparesis.
3. Other gastroparesis symptoms include early satiety, post-prandial fullness and abdominal discomfort.
4. Takeda is the largest pharmaceutical company in Japan.
5. Takeda has been involved in the gastroenterology field for more than 25 years.
More articles on GI & endoscopy:
AGA, other societies express concerns about alternate payment model adoption to CMS: 4 notes
4 insights on increasing anesthesia use in outpatient GI procedures
GI physician leader to know: Dr. Jeffrey Dunkelberg of University of Iowa Hospitals
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
